Terminal inhibitors such as eculizumab effectively block C5 cleavage and intravascular hemolysis, yet many patients still develop anemia, reticulocytosis, and fatigue from C3-mediated extravascular hemolysis. The gene discussed is C3; the disease is anemia (phenotype).